Details for Patent: 9,926,559
Which drugs does patent 9,926,559 protect, and when does it expire?
Patent 9,926,559 protects SPINRAZA and is included in one NDA.
This patent has two patent family members in two countries.
Summary for Patent: 9,926,559
| Title: | Compositions and methods for modulation of SMN2 splicing in a subject | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | C. Frank Bennett, Gene Hung, Frank Rigo | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Biogen MA Inc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US14/760,171 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,926,559 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 9,926,559: Nusinersen Patent Scope, Expiration, Orange Book Status, and Generic Entry RiskUS Patent 9,926,559 protects a narrow but commercially important method of administering nusinersen, marketed as Spinraza. The patent covers the 18-nucleotide antisense oligonucleotide sequence, its 2'-MOE and phosphorothioate chemistry, intrathecal bolus delivery, specified dose levels, age-based administration volumes, needle gauges, lumbar injection location, and an initial repeat dose 12 to 18 days later. The patent is assigned to Ionis Pharmaceuticals and is part of the Spinraza patent estate licensed to Biogen. Its nominal patent term extends to June 5, 2034, subject to any applicable patent-term adjustment, terminal-disclaimer restrictions, or other USPTO corrections. FDA approval of Spinraza occurred on December 23, 2016, and the product also received orphan-drug exclusivity and pediatric exclusivity. [1-4] What drug does US Patent 9,926,559 protect?US 9,926,559 protects a treatment method using nusinersen, an antisense oligonucleotide directed against the SMN2 pre-mRNA transcript. The claimed oligonucleotide has these defining characteristics:
The patent does not broadly cover every antisense treatment for SMA. It requires the claimed sequence and chemistry in combination with intrathecal dosing at one of the stated dose levels. Nusinersen binds to an intronic splicing silencer region in SMN2 pre-mRNA. The treatment promotes inclusion of exon 7, increasing production of full-length survival motor neuron protein. The mechanism distinguishes nusinersen from risdiplam, a small-molecule SMN2 splicing modifier, and onasemnogene abeparvovec, an AAV-based gene-replacement therapy. What are the independent and dependent claim limitations?Claim 1 is the principal enforceable method claim. It requires proof of every limitation. A party practices claim 1 only if it:
The dependent claims narrow the administration procedure.
Claim 10 is directed to the early loading regimen. The 12-to-18-day interval overlaps the approximately two-week repeat dosing used in the initial Spinraza loading schedule. How broad is the scope of US 9,926,559?The patent has strong literal coverage of the approved Spinraza regimen but limited coverage outside that regimen. Sequence and chemistry limitationsThe sequence limitation sharply narrows the claim. A competing antisense oligonucleotide with a different sequence would not literally satisfy claim 1, even if it targeted SMN2 and produced the same biological effect. The chemistry limitations are also cumulative. The claimed compound must have:
A molecule using phosphodiester linkages, phosphorodiamidate morpholino chemistry, constrained ethyl chemistry, 2'-O-methyl substitutions, or an alternative cytosine modification would fall outside the literal wording of claim 1. Dose and route limitationsThe claim does not cover every intrathecal dose of nusinersen. It specifies five discrete dose levels. A 12.1 mg dose or a materially different dosing regimen would not literally meet the stated dose limitation. The route requirement is also specific. Intravenous, subcutaneous, intramuscular, epidural, or oral delivery would not satisfy the claim. Intrathecal administration into the cerebrospinal-fluid compartment is central to the patent. Method-of-treatment limitationsThe patent is a method patent, not a composition patent. It generally requires evidence that the accused party administered the claimed product to a human SMA patient. Manufacture, sale, or possession of nusinersen may implicate other patents, regulatory provisions, or contributory-infringement theories, but those activities do not automatically satisfy the treatment steps in claim 1. What patent protects the nusinersen sequence and composition?US 9,926,559 is one component of the broader nusinersen estate. Earlier Ionis patents cover the antisense sequence, SMN2 modulation, oligonucleotide compositions, and therapeutic use more generally. The foundational estate includes patents directed to:
US Patent 8,980,853, titled "Antisense modulation of survival motor neuron 2 expression," is commonly identified as a foundational Spinraza patent. US 9,926,559 adds regimen-specific protection, particularly the intrathecal doses and age-based administration volumes. [5] The commercial effect is cumulative. A generic or follow-on developer may need to avoid several patents rather than design around US 9,926,559 alone. When does US Patent 9,926,559 lose exclusivity?The nominal expiration date is June 5, 2034.
FDA regulatory exclusivity and patent protection are separate. The end of orphan or pediatric exclusivity did not eliminate the patent barrier. A generic applicant could potentially file an ANDA after the relevant statutory filing period, but commercial launch would remain subject to listed patents and any litigation stay. What is the Orange Book status of Spinraza?Spinraza is approved under NDA 209531. Biogen is the commercial sponsor, while Ionis is the originator of the antisense technology and a key patent holder or licensor. The Orange Book identifies patent protection for approved drug products through patent-number and use-code listings. Spinraza's listed protection is relevant to abbreviated new drug applications that rely on the Spinraza reference product. A generic applicant may make:
US 9,926,559 is particularly relevant to a generic label that includes the patented intrathecal dosing regimen. A section viii carve-out could be difficult if the approved generic labeling necessarily reproduces the same dose and loading instructions. FDA Orange Book treatment does not determine ultimate patent validity. It determines the regulatory consequences of a certification and can trigger the 30-month stay under the Hatch-Waxman framework if the NDA holder or patent owner files an infringement action within the statutory period. [1,6] Have generic companies filed Paragraph IV challenges to Spinraza?No publicly established Paragraph IV litigation record is identified for US 9,926,559 in the materials supporting this analysis. That does not eliminate future challenge risk. The principal challenge window would arise when an ANDA applicant seeks approval for a nusinersen product and certifies against the listed Spinraza patents. The likely dispute would focus on:
A Paragraph IV case would likely involve US 9,926,559 together with earlier composition and SMN2 patents. The commercial risk would therefore depend on the entire Orange Book estate, not this patent in isolation. How strong is the patent estate for Spinraza?US 9,926,559 has high literal-infringement strength against a conventional generic that copies the Spinraza label and product characteristics. Its principal strengths are:
Its principal vulnerabilities are claim narrowness and potential validity challenges. A challenger could argue that the selected doses and administration parameters would have been obvious in view of earlier SMA antisense studies, clinical protocols, or routine dose optimization. The patent owner would counter that the claimed combinations reflect specific clinical development work and are not merely arbitrary selections. The patent is stronger against an identical generic regimen than against a modified regimen. A product using the same nusinersen sequence but a different dose may avoid claim 1 while remaining exposed to other patents or infringement theories. What formulation and manufacturing patents affect generic entry?US 9,926,559 does not primarily claim a formulation. It claims treatment using a chemically defined oligonucleotide and specifies administration volumes in dependent claims. Generic entry may still face separate barriers involving:
For an antisense oligonucleotide, regulatory similarity may require extensive analytical data because conventional small-molecule bioequivalence methods do not fully capture sequence identity, impurity profile, chain-length distribution, and chemical substitution patterns. These manufacturing issues are not automatically covered by US 9,926,559, but they can increase the practical cost and timing of generic development. What licensing deal controls Spinraza commercialization?Ionis and Biogen entered into a collaboration covering nusinersen development and commercialization. Biogen obtained rights to develop and commercialize Spinraza globally, while Ionis retained economic participation through upfront consideration, milestone payments, and royalties. The collaboration made Biogen the principal regulatory and commercial counterparty for Spinraza, while Ionis remained central to the underlying antisense technology and patent position. [7] This structure matters in litigation and licensing because a generic challenge may involve both the NDA holder and patent owner. It also affects settlement authority, royalty economics, and allocation of enforcement responsibilities. How does Spinraza compare with competing SMA drugs?
Spinraza retains a distinct patent position because its protection combines a defined antisense sequence with a specific intrathecal clinical regimen. Evrysdi and Zolgensma compete therapeutically but do not directly avoid or invalidate the nusinersen claims merely by using different modalities. What generic launch scenarios exist?The most plausible launch scenarios are:
The first scenario carries the highest litigation exposure. The second reduces exposure to this patent but may not provide freedom to operate across the full Spinraza estate. Key Takeaways
FAQsDoes US 9,926,559 cover all nusinersen products?No. It covers a specific chemical configuration and specified intrathecal SMA treatment regimen. Other nusinersen products may still face separate patents. Can a generic avoid US 9,926,559 by changing the injection needle?Changing the needle could avoid claims 2 and 3, but it would not avoid claim 1. The generic would need to avoid the independent claim or invalidate it. Does a different intrathecal dose avoid the patent?A materially different dose may avoid the literal dose limitation in claim 1, but other Spinraza patents could still apply. Is US 9,926,559 a composition patent?No. It is principally a method patent. The claimed subject matter is the treatment of a human SMA patient using a defined antisense oligonucleotide and administration regimen. Does the patent cover risdiplam or gene therapy for SMA?No. Risdiplam is a small molecule, and onasemnogene abeparvovec is an AAV gene therapy. Neither product satisfies the claimed nusinersen oligonucleotide limitations. References
More… ↓ |
Drugs Protected by US Patent 9,926,559
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | RX | Yes | Yes | 9,926,559 | ⤷ Start Trial | TREATMENT OF SPINAL MUSCULAR ATROPHY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,926,559
| PCT Information | |||
| PCT Filed | January 09, 2014 | PCT Application Number: | PCT/US2014/010930 |
| PCT Publication Date: | July 17, 2014 | PCT Publication Number: | WO2014/110291 |
International Family Members for US Patent 9,926,559
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2943225 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2014110291 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
